

Online Figure-3. STAT3 enhancing SeSNV – rs351855-A supresses the CD8/Treg ratio in the TME in SNV knock-in GEMM for breast and lung cancers. (A) Numbers of $CD4^{+}CD25^{+}FOXP3^{+}$ T cells in tumour-bearing breast tissue of *Fgfr4*$^{rs351855\text{-}G/G}$;*Wap-Tgfα*, *Fgfr4*$^{rs351855\text{-}G/A}$;*Wap-Tgfα*, and *Fgfr4*$^{rs351855\text{-}A/A}$;*Wap-Tgfα* mice (mean ± SEM, n = 5, **P < 0.01, ***P < 0.001). (D) Numbers of $CD4^{+}CD25^{+}FOXP3^{+}$ T cells in tumour-bearing lungs of *Fgfr4*$^{rs351855\text{-}G/G}$;*SPC-CrafBxB*, *Fgfr4*$^{rs351855\text{-}G/A}$;*SPC-CrafBxB*, and *Fgfr4*$^{rs351855\text{-}A/A}$;*SPC-CrafBxB* mice (mean ± SEM, n = 4–7, **P < 0.01, ***P < 0.001). (B) Quantification of IL10 in serum of tumour-bearing *Fgfr4*$^{rs351855\text{-}G/G}$;*Wap-Tgfα* and *Fgfr4*$^{rs351855\text{-}A/A}$;*Wap-Tgfα* breast cancer mice (mean ± SEM, n = 6–9, **P < 0.01) and (E) tumour-bearing *Fgfr4*$^{rs351855\text{-}G/G}$;*SPC-CrafBxB* and *Fgfr4*$^{rs351855\text{-}A/A}$;*SPC-CrafBxB* lung cancer mice (mean ± SEM, n = 8–12, ***P < 0.001) by ELISA. (C) Quantification of tumour-infiltrating CD8 T cells in tumour nodules by immunostaining for CD8 in breast tumour-bearing *Fgfr4*$^{rs351855\text{-}G/G}$;*Wap-Tgfα* and *Fgfr4*$^{rs351855\text{-}A/A}$;*Wap-Tgfα* mice and (F) lung tumour-bearing *Fgfr4*$^{rs351855\text{-}G/G}$;*SPC-CrafBxB* and *Fgfr4*$^{rs351855\text{-}A/A}$;*SPC-CrafBxB* (mean ± SEM, n = 19–26, ****P < 0.0001, ***P < 0.001, 2-tailed unpaired t test with Welch's correction). Insets: Representative images from IF staining of tumour sections (×20 magnification) depicting tumour-infiltrating CD8 T cells in lung and breast tumours (DAPI-blue, CD8-green). The red text in the figure denotes the rs351855-A allele (Figure Taken from Kogan et al JCI 2018, doi: 10.1172/JCI96708).